Imunon, Inc. Files Amendment No. 1 to S-1 Registration Statement
Ticker: IMNN · Form: S-1/A · Filed: Jan 18, 2024 · CIK: 749647
| Field | Detail |
|---|---|
| Company | Imunon, INC. (IMNN) |
| Form Type | S-1/A |
| Filed Date | Jan 18, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01, $0.66, $0, $0.0001, $100,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: Imunon, IMNN, S-1/A, SEC Filing, Registration Statement
TL;DR
<b>Imunon, Inc. has filed an S-1/A amendment for its registration statement, indicating ongoing efforts to offer securities.</b>
AI Summary
Imunon, Inc. (IMNN) filed a Amended IPO Registration (S-1/A) with the SEC on January 18, 2024. Imunon, Inc. (formerly Celsion Corp) filed an S-1/A amendment on January 18, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. The principal executive offices are located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648. The filing is a registration statement under the Securities Act of 1933, with registration number 333-276174. Imunon, Inc. is classified as a non-accelerated filer and a smaller reporting company.
Why It Matters
For investors and stakeholders tracking Imunon, Inc., this filing contains several important signals. This S-1/A filing is a procedural step for Imunon, Inc. to register securities, which is a prerequisite for public offerings or further capital raises. The classification as a non-accelerated filer and smaller reporting company suggests Imunon, Inc. may have a market capitalization below certain thresholds, potentially impacting investor perception and regulatory scrutiny.
Risk Assessment
Risk Level: low — Imunon, Inc. shows low risk based on this filing. The risk is low as this is a standard S-1/A filing for registration purposes and does not contain new financial performance data or significant business updates that would immediately impact the company's valuation.
Analyst Insight
Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds, to assess the impact on Imunon, Inc.'s capital structure and growth strategy.
Key Numbers
- 2024-01-18 — Filing Date (Date of filing for the S-1/A amendment)
- 2024-01-17 — Date as of Change (Date as of change for the filing)
- 333-276174 — Registration Number (SEC registration number for the offering)
- 08648 — ZIP Code (ZIP code for principal executive offices)
- 52-1256615 — IRS Employer Identification No. (IRS EIN for Imunon, Inc.)
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Celsion Corp (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Lawrenceville, NJ (location) — Address of principal executive offices
- Corinne Le Goff (person) — President and Chief Executive Officer
- Megan Gates, Esq. (person) — Copies to counsel
- Covington & Burling LLP (company) — Counsel
- 333-276174 (registration_number) — Registration number
Forward-Looking Statements
- Imunon, Inc. will initiate a public offering of securities within the next 12 months. (Imunon, Inc.) — medium confidence, target: 2025-01-17
FAQ
When did Imunon, Inc. file this S-1/A?
Imunon, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on January 18, 2024.
What is a S-1/A filing?
A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Imunon, Inc. (IMNN).
Where can I read the original S-1/A filing from Imunon, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Imunon, Inc..
What are the key takeaways from Imunon, Inc.'s S-1/A?
Imunon, Inc. filed this S-1/A on January 18, 2024. Key takeaways: Imunon, Inc. (formerly Celsion Corp) filed an S-1/A amendment on January 18, 2024.. The company is incorporated in Delaware and its fiscal year ends on December 31.. The principal executive offices are located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648..
Is Imunon, Inc. a risky investment based on this filing?
Based on this S-1/A, Imunon, Inc. presents a relatively low-risk profile. The risk is low as this is a standard S-1/A filing for registration purposes and does not contain new financial performance data or significant business updates that would immediately impact the company's valuation.
What should investors do after reading Imunon, Inc.'s S-1/A?
Monitor future filings for details on the proposed offering, including the number of shares, pricing, and use of proceeds, to assess the impact on Imunon, Inc.'s capital structure and growth strategy. The overall sentiment from this filing is neutral.
How does Imunon, Inc. compare to its industry peers?
Imunon, Inc. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products.
Are there regulatory concerns for Imunon, Inc.?
The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.
Industry Context
Imunon, Inc. operates in the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products.
Regulatory Implications
The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.
What Investors Should Do
- Review the full S-1/A filing for details on the securities being registered, including type, number, and proposed offering price.
- Track subsequent SEC filings from Imunon, Inc. for updates on the offering's progress and any material business developments.
- Analyze the company's financial health and business strategy once more detailed information becomes available in future filings.
Key Dates
- 2024-01-18: Filing of Amendment No. 1 to Form S-1 — Updates and amends the initial registration statement for securities offering.
Year-Over-Year Comparison
This is an amendment to a previous S-1 filing, indicating a continuation of the registration process rather than a new filing.
Filing Stats: 4,469 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-01-17 18:03:33
Key Financial Figures
- $0.01 — 2 shares of our common stock, par value $0.01 (“ Common Stock ”), togethe
- $0.66 — on an assumed public offering price of $0.66 per share of Common Stock and accompany
- $0 — an assumed exercise price per share of $0.66, equal to the assumed public offerin
- $0.0001 — rice of each pre-funded warrant will be $0.0001 per share. The pre-funded warrants will
- $100,000 — lated legal expenses in an amount up to $100,000 and $25,000 for non-accountable expense
- $25,000 — xpenses in an amount up to $100,000 and $25,000 for non-accountable expenses. See &ldqu
Filing Documents
- forms-1a.htm (S-1/A) — 846KB
- ex1-1.htm (EX-1.1) — 82KB
- ex4-7.htm (EX-4.7) — 102KB
- ex4-8.htm (EX-4.8) — 83KB
- ex5-1.htm (EX-5.1) — 16KB
- ex10-25.htm (EX-10.25) — 299KB
- ex23-1.htm (EX-23.1) — 4KB
- logo_001.jpg (GRAPHIC) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 94KB
- ex5-1_003.jpg (GRAPHIC) — 3KB
- 0001493152-24-002801.txt ( ) — 1585KB
DILUTION
DILUTION 10 USE OF PROCEEDS 11 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 12 EXECUTIVE AND DIRECTOR COMPENSATION 15 EQUITY COMPENSATION PLAN INFORMATION 29 BENEFICIAL OWNERSHIP OF COMMON STOCK 30 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 31 DESCRIPTION OF CAPITAL STOCK 32 DESCRIPTION OF SECURITIES TO BE REGISTERED 37 MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS 40 DIVIDEND POLICY 47 PLAN OF DISTRIBUTION 48 LEGAL MATTERS 51 EXPERTS 51 WHERE YOU CAN FIND MORE INFORMATION 51 INCORPORATION OF CERTAIN INFORMATION BY REFERENCE 52 i CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS Certain of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”). Forward-looking statements may relate to such matters as anticipated financial performance, business prospects, technological developments, product pipelines, clinical trials and research and development activities, the adequacy of capital reserves and anticipated operating results and cash expenditures, current and potential collaborations, strategic alternatives and other aspects of our present and future business operations and similar matters. These statements involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Such statements include, without limitation: any
Business
Business Overview Imunon is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across four modalities. The first modality, TheraPlas ® , is being developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine ® , is being developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases. The third modality, FixPlas ® , concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas ® , is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company is conducting Investigational New Drug (IND)-enabling preclinical studies for the development of a COVID-19 booster vaccine (IMNN-101) and a treatment for the LASSA virus (IMNN-102). The Company has also initiated preclinical work to develop a Trp2 tumor associated antigen cancer vaccine in melanoma (IMNN-201). Imunon will continue to leverage these modalities and to advance the technological frontier of plasmid DNA